Kindred Biosciences Announces Half-Life Extension Technology For

0
64
Cision

SAN FRANCISCO. January 8, 2020 / PRNewswire / – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial biopharmaceutical company focused on saving and improving pet lives, announced today that it has developed a technology that can help reduce the half-life of Dog antibodies can be extended up to 30% in triplicate. A patent application for this technology has been filed.

The study included 12 dogs, including four groups with different modifications using KindredBio technology and a wild-type dog antibody as a control. A prolongation of the half-life was observed in all dogs except for the wild type, the extent of the prolongation against native antibodies being two to three times. Further studies to further differentiate between lead molecules and to expand the sample size are planned for 2020.

Half-life prolongation technologies can improve therapeutic performance in a variety of ways. A reduced dose frequency and / or dose amount can lead to an improvement in patient comfort and compliance. It can also significantly reduce the cost of goods and improve profitability and market positioning. In addition, a higher drug concentration using the same dose and interval as the starting antibody may result in prolonged drug exposure and possibly improved efficacy.

"This innovation is a major breakthrough with a wide impact on our biologicals portfolio," said KindredBio's chief executive officer. Richard Chin"Our market research shows that longer dosing intervals are a critical factor in economic success. This platform technology has the potential to significantly improve the market position of KindredBio's biological pipeline by creating first-class and more profitable veterinary drugs while offering out-licensing opportunities."

"We expect longer-term therapeutics and improved comfort to accelerate the switch to antibody-oriented veterinary medicine. KindredBio is proud to be a leading provider of pet biologics, with an extensive pipeline and state-of-the-art biologics manufacturing capabilities." a first class team of protein engineers. "

KindredBios Canine Biologics pipeline includes treatments in development for neurodermatitis, inflammatory bowel disease and parvovirus.

KindredBio will discuss and answer questions about the results of the study today 4.30 p.m. Easter time / 1.30 p.m. Pacific time, Interested parties can access the call by calling toll-free (855) 433-0927 from the United States or (484) 756-4262 from abroad and using conference ID 7499973. The call is also broadcast over this link for 30 days.

About related life sciences

Kindred Biosciences is a commercial biopharmaceutical company focused on saving and improving pet life. His mission is to bring pets the same safe and effective medicines that family members enjoy. The company's strategy is to identify compounds and targets that have already been proven to be safe and effective in humans and to develop therapeutics for dogs, cats and horses based on these validated compounds and targets. KindredBio has a wide range of new drugs and biologicals that are in development in many therapeutic classes. The company has two approved drugs, Mirataz® (transdermal mirtazapine ointment) and Zimeta ™ (dipyrone injection).

Forward-looking statements

This press release contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. All statements contained in this press release that are not historical facts should be considered forward-looking statements, including but not limited to statements about our expectations in Regarding testing, regulatory approval, manufacturing, distribution and marketing of our current and future product candidates, as well as statements about our expected income, expenses, margins, profits and the use of cash.

These forward-looking statements are based on our current expectations. These statements are not commitments or guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results to differ materially from future results expressed or implied in the forward-looking statements. These risks include, but are not limited to: our limited business history and anticipation of loss for the foreseeable future; the lack of significant revenue from our products and product candidates for the foreseeable future; the likelihood that our sales will vary from quarter to quarter; our potential inability to obtain the necessary additional funding; our significant dependence on the success of our products and our key product candidates, who may not be successfully commercialized even if they are approved for marketing; the impact of competition; our possible inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to carry out some of our development activities; our dependence on third party manufacturers in the delivery of our products and our product candidates; Uncertainties about the results of studies related to our product candidates; our possible failure to attract and retain executives and key researchers; Uncertainty about our ability to build a satisfactory sales organization; our significant cost of operating as a public company; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and product candidates; potential claims by third parties related to infringement of their patents and other intellectual property rights; our possible failure to meet regulatory requirements that are subject to change; the possible volatility of our share price; and significant control over our business through our major shareholders and management.

For a further description of these risks and other risks to which we are exposed, see the risk factors described in our filings with the United States Securities and Exchange Commission, including the risk factors under the heading "Risk Factors." "Our annual financial statements include Form 10-K reports and any subsequent updates that may be included in our Form 10-Q quarterly reports filed with the SEC. Due to the risks described above and our filings with the SEC, actual results may differ materially from the forward-looking statements contained in this press release. The forward-looking statements contained in this press release are only effective as of the date of this press release and we are under no obligation to update or revise these statements unless required by law.

The results reported in this press release have not been reviewed by the United States Department of Agriculture Center for Veterinary Biologics.

contacts

Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-9. 3438

Cision View the original content for downloading multimedia content: http://www.prnewswire.com/news-releases/kindred-biosciences- announces the technology to extend the half-life for rabbit body 300983726.html

SOURCE Kindred Biosciences, Inc.